GGrantIndex
← Leaderboards

David K. Simon

Beth Israel Deaconess Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$9,625,206
Attributed
$10,726,009
Total exposure
16
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,726,009 · 16

By mechanism

R01$4,571,308 · 3
R21$3,321,357 · 7
U10$954,624 · 1
K02$716,930 · 1
R56$612,500 · 1
R03$317,630 · 2

Top collaborators

Most similar at Beth Israel Deaconess Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Mitochondria”

Research focus

MitochondriaParkinson DiseaseOxidative StressSubstantia Nigra StructureNeuronsBrainAlpha SynucleinPlayComplexMitochondrial DysfunctionProteinsFunctional DisorderDopaminergic NeuronCellsPathogenesisAntioxidantsMutantMutationAnimal ModelMitochondrial DnaNeuroprotectionOverexpressionPredispositionMitochondrial Dna Mutation

Grant awards (48)

Targeting the FBXW7/PGC1 Pathway as a Therapeutic Strategy for Parkinson's Disease$590,222
R01 · FY2025 · NS · contact PI
Targeting the FBXW7/PGC1 Pathway as a Therapeutic Strategy for Parkinson's Disease$665,971
R01 · FY2024 · NS · contact PI
USP30 Inhibition as a Therapeutic Strategy in Parkinson's Disease$475,475
R21 · FY2023 · NS · contact PI
VPS35 as a therapeutic target in Parkinson's disease$475,475
R21 · FY2023 · NS · contact PI
Autophagy-Proteasome Cross-Talk in Parkinson's Pathogenesis$612,500
R56 · FY2019 · NS · contact PI
USP30 as a Therapeutic Target in Parkinson’s Disease$481,250
R21 · FY2019 · NS · contact PI
PGC-1alpha and Pitx3 as individual and combined targets for neuroprotection$379,991
R01 · FY2018 · NS · contact PI
Mitochondrial mechanisms and vulnerability to alpha-synuclein toxicity$259,500
R21 · FY2018 · NS · contact PI
PGC-1alpha and Pitx3 as individual and combined targets for neuroprotection$379,991
R01 · FY2017 · NS · contact PI
Mitochondrial mechanisms and vulnerability to alpha-synuclein toxicity$216,250
R21 · FY2017 · NS · contact PI
PGC-1alpha and Pitx3 as individual and combined targets for neuroprotection$379,991
R01 · FY2016 · NS · contact PI
PGC-1alpha and Pitx3 as individual and combined targets for neuroprotection$378,722
R01 · FY2015 · NS · contact PI
PGC-1alpha and Pitx3 as individual and combined targets for neuroprotection$392,220
R01 · FY2014 · NS · contact PI
Role of urate in protecting mitochondrial function in the brain$252,323
R21 · FY2014 · NS
Role of urate in protecting mitochondrial function in the brain$217,616
R21 · FY2013 · NS
Mechanisms of Protection in the Brain by Physical Exercise in Polg Mutator Mice$209,888
R21 · FY2013 · NS · contact PI
Limited Competition for Continuation of the NIH Exploratory Trials in Parkinson's$76,285
U10 · FY2013 · NS · contact PI
Mechanisms of Protection in the Brain by Physical Exercise in Polg Mutator Mice$261,000
R21 · FY2012 · NS · contact PI
Mitophagy-driven selection against heteroplasmic mitochondrial DNA mutations$217,500
R21 · FY2012 · NS · contact PI
Parkinson Disease Neuroprotection Clinical Trial$91,061
U10 · FY2012 · NS · contact PI
Oxidative Stress, alpha-Synuclein, and mtDNA Mutations in Parkinson's Disease$291,550
R01 · FY2011 · NS · contact PI
Mitophagy-driven selection against heteroplasmic mitochondrial DNA mutations$255,080
R21 · FY2011 · NS · contact PI
Parkinson Disease Neuroprotection Clinical Trial$97,968
U10 · FY2011 · NS · contact PI
Impact of Somatic Mitochondrial DNA Point Mutations in the Aging Brain$73,590
R03 · FY2011 · AG · contact PI
Oxidative Stress, alpha-Synuclein, and mtDNA Mutations in Parkinson's Disease$294,525
R01 · FY2010 · NS · contact PI
Parkinson Disease Neuroprotection Clinical Trial$107,124
U10 · FY2010 · NS · contact PI
Impact of Somatic Mitochondrial DNA Point Mutations in the Aging Brain$76,505
R03 · FY2010 · AG · contact PI
Parkinson Disease Neuroprotection Clinical Trial$42,600
U10 · FY2010 · NS · contact PI
Oxidative Stress, alpha-Synuclein, and mtDNA Mutations in Parkinson's Disease$297,500
R01 · FY2009 · NS · contact PI
Parkinson Disease Neuroprotection Clinical Trial$143,373
U10 · FY2009 · NS · contact PI
Oxidative Stress, alpha-Synuclein, and mtDNA Mutations in Parkinson's Disease$297,500
R01 · FY2008 · NS · contact PI
Parkinson Disease Neuroprotection Clinical Trial$148,658
U10 · FY2008 · NS · contact PI
Oxidative Stress, alpha-Synuclein, and mtDNA Mutations in Parkinson's Disease$223,125
R01 · FY2007 · NS · contact PI
Somatic Mitochondrial DNA Mutations in Neurons and Glia$82,535
R03 · FY2007 · NS · contact PI
Parkinson Disease Neuroprotection Clinical Trial$59,405
U10 · FY2007 · NS · contact PI
Acquired Mitochondrial DNA Mutations in the Brain$110,986
K02 · FY2006 · NS · contact PI
Somatic Mitochondiral DNA Mutations in Neurons and Glia$85,000
R03 · FY2006 · NS · contact PI
Parkinson Disease Neuroprotection Clinical Trial$28,350
U10 · FY2006 · NS · contact PI
Parkinson Disease Neuroprotection Clinical Trial$14,000
U10 · FY2006 · NS · contact PI
Acquired Mitochondrial DNA Mutations in the Brain$110,986
K02 · FY2005 · NS
Parkinson Disease Neuroprotection Clinical Trial$20,850
U10 · FY2005 · NS
Acquired Mitochondrial DNA Mutations in the Brain$164,986
K02 · FY2004 · NS
Acquired Mitochondrial DNA Mutations in the Brain$164,986
K02 · FY2003 · NS
Parkinson Disease Neuroprotection Clinical Trial$62,475
U10 · FY2003 · NS
Acquired Mitochondrial DNA Mutations in the Brain$164,986
K02 · FY2002 · NS
Parkinson Disease Neuroprotection Clinical Trial$62,475
U10 · FY2002 · NS
OXIDATIVE STRESS AND PARKINSONS DISEASE$110,430
K08 · FY2001 · NS
OXIDATIVE STRESS AND PARKINSONS DISEASE$121,230
K08 · FY2000 · NS